Publications by authors named "Jelena Colic"
Background: The EULAR recommendations for the treatment of systemic sclerosis (SSc) were updated in 2017, informed by a systematic literature review (SLR) completed in 2014.
Objectives: The aim of this new SLR was to provide the most up-to-date literature to underpin contemporary EULAR recommendations for the management of SSc.
Methods: 30 searches for 30 interventions (including several outcomes/clinical questions), and 1 dedicated search (with several interventions) for calcinosis were prioritised by the task force.
EULAR recommendations for the treatment of systemic sclerosis: 2023 update.
Ann Rheum Dis
January 2025
Objectives: To update the 2017 European Alliance of Associations for Rheumatology (EULAR) recommendations for treatment of systemic sclerosis (SSc), incorporating new evidence and therapies.
Methods: An international task force was convened in line with EULAR standard operating procedures. A nominal group technique exercise was performed in two rounds to define questions underpinning a subsequent systematic literature review.
Extracellular vesicles and interstitial lung disease in systemic sclerosis: State of the art!
Rheumatol Immunol Res
September 2024
Investigational drugs for the treatment of scleroderma: what's new?
Expert Opin Investig Drugs
November 2023
Introduction: Systemic sclerosis (SSc) is an orphan, chronic, autoimmune, fibrotic disease with unknown etiology characterized by progressive fibrosis of the skin and internal organs. SSc has the highest mortality, the deadliest among the connective tissue diseases, despite the introduction of new treatment options in the past decades.
Areas Covered: The aim of the current systematic review was to investigate new targeted therapy and their impact on disease progression, mainly focusing on phase I and II clinical trials within the past three years.
Article Synopsis
- The study evaluated thrombin generation and fibrin formation in systemic sclerosis patients, specifically focusing on those with a history of digital ulcers (DUs).
- Significant differences in thrombin levels and clot lysis times were found between patients with DUs and healthy controls, indicating a correlation with disease severity.
- Over a follow-up of 1.5 years, prolonged clot lysis and other factors were identified as predictors for the development of new DUs, suggesting that impaired fibrinolysis contributes to complications in systemic sclerosis.
Microparticles in systemic sclerosis, targets or tools to control fibrosis: This is the question!
J Scleroderma Relat Disord
February 2020
Systemic sclerosis is the main systemic fibrotic disease with unknown etiology characterized by peripheral microvascular injury, activation of immune system, and wide-spread progressive fibrosis. Microparticles can be derived from any cell type during normal cellular differentiation, senescence, and apoptosis, and also upon cellular activation. Carrying along a broad range of surface cytoplasmic and nuclear molecules of originating cells, microparticles are closely implicated in inflammation, thrombosis, angiogenesis, and immunopathogenesis.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to evaluate the link between salivary ultrasonography (sUS) findings and disease activity in patients with primary Sjogren's syndrome (pSS), exploring sUS's potential as a prognostic tool.
- In a group of 303 pSS patients, a significant number had pathological sUS scores, with higher disease activity correlating to worse sUS findings, indicating that patients with severe sUS scores have a higher chance of higher disease activity.
- The findings suggest that a de Vita sUS score of 5 or higher can serve as a risk factor for moderate to high disease activity, though its ability to accurately identify such cases is limited in sensitivity compared to its
Aims: Autologous conditioned serum (ACS; marketed as Orthokine®) is an autologous blood product that has previously shown efficacy in treatment of joint osteoarthritis, spinal radiculopathy, tendon and muscle injuries in randomized controlled trials. In this 24-week, randomized, double-blind study, we compared the efficacy and safety of ACS with glucocorticoid (betamethasone) injections in chronic supraspinatus tendinopathy patients.
Material And Methods: Thirty-two patients with chronic supraspinatus tendinopathy were enrolled in the study.